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Abstract 
The purpose of this project was to improve statin therapy adherence among diabetic patients 
aged 65 and older treated at a small family practice clinic in western San Antonio. Additionally, 
the project aimed to decrease low density lipoprotein cholesterol levels in this patient population 
as recommended to 70 mg/dl or less. Diabetic patients are more likely to die from a cardiac event 
than patients without diabetes. Statin therapy is an important factor in lowering cholesterol, 
which reduces the patient’s risk for atherosclerosis. Educating patients aged 65 and older about 
the role of statin therapy in preventing cardiovascular events, stroke, and vascular compromise 
may increase medication adherence in this population, resulting in appropriate low density 
lipoprotein levels for prevention of these serious comorbidities. 135 chart reviews took place, 
from which thirty-three patients were identified for the education intervention. The patients were 
screened for medication adherence using the Morisky Medication Adherence Scale survey before 
and after the intervention period to measure adherence to statin therapy. Education about 
cholesterol and statin therapy was provided during the patient appointment, and a handout was 
provided for reinforcement of education. Low density lipoprotein levels were drawn by the clinic 
laboratory before and after the intervention period to measure improvement. Results showed 
significant medication adherence increase and low density lipoprotein level decrease among 
project participants after the 10-week implementation, though the target low density lipoprotein 
level of 70 mg/dl or less was not met.  
Keywords: hyperlipidemia, diabetes, T2DM, statin therapy, cardiovascular disease, medication 
adherence 
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 Diabetes and cardiovascular disease are two of the most common causes of death 
worldwide, and though there have been many medical advances in treatment of these two 
diseases, patients 65 years and older with diabetes remain at high risk for death due to 
cardiovascular disease. The internet has expanded the amount of knowledge and 
recommendations open to the world; however, this vulnerable population is not one that is 
familiar with the worldwide web. In many instances, paper education is still a valuable tool that 
can be utilized to educate patients in this age range.  
 Many patients 65 years and older are victims of polypharmacy, and this can lead to 
decreased medication adherence. As a result, these patients are at higher risk of cardiovascular 
disease not only because they do not know how to use the internet to find educational 
information, but because they may forget to take their cholesterol medication or they cannot 
afford it because of all of the other medications they may be taking concurrently.  
Statement of the Problem 
 Type 2 diabetes mellitus (T2DM) is a chronic disease associated with issues such as a 
sedentary lifestyle and nutritional mismanagement of dietary patterns (Osonoi et al., 2016). 
T2DM affects anywhere from 341 million to 371 million people in the world (Mohammed, Al-
Haj, Phung, Sun & Morisky, 2016), and heart disease is the leading cause of death worldwide 
(Osonoi et al., 2016). Most patients diagnosed with T2DM are not knowledgeable about the 
disease and fail to implement a healthy lifestyle. This pertains to adherence to medications that 
can control the disease and prevent further complications as well. Complications of T2DM 
include heart disease, stroke, renal failure, peripheral neuropathy and extremity amputation, and 
diabetic retinopathy which can ultimately cause blindness (Jalilian, Motlagh, Solhi, & 
Gharibnavaz, 2014). Proper management of T2DM can lead to better quality of life, and 
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prevention of comorbidities that can increase incidence of morbidity and mortality related to the 
complications of this disease.  
 One of the most frequently encountered comorbidities of T2DM, and one of the most 
fatal, is cardiovascular disease. Cardiovascular disease pertains to disease of the veins, arteries, 
and the heart, and is mostly due to atherosclerosis. Atherosclerosis is defined by the American 
Heart Association as a condition that develops when plaque made of cholesterol builds up in the 
walls of the arteries and makes them narrow and inflexible (American Heart Association, 2016). 
This makes it extremely difficult for blood to flow, and with less area to pass through, it is easier 
for a blood clot to form, causing a heart attack, and in the brain, a stroke (American Heart 
Association, 2016).  
 Both the American Heart Association and the American Diabetes Association 
recommend the initiation of statin therapy in the diabetic patient, as these patients are at high risk 
for cardiovascular disease related to atherosclerosis. However, when patients are given one more 
medication that is not for something already affecting their overall health, this generally does not 
persuade them to take said medication. The medications these patients have already been issued 
to control their T2DM not taken either because they feel fine or they have forgotten. Medication 
adherence is a major concern, as it is estimated that close to 50% of diabetics are non-compliant 
with medications of some sort (Mohammed et al., 2016). Non-adherence to medications can lead 
to hospitalization, emergency interventions, and even death (Mohammed et al., 2016). Some 
predictors of medication non-adherence are difficulty reading prescription labels, increased 
intensity of treatment, increased symptom burden, inadequate self-monitoring, and inadequate 
disease knowledge (DiBonaventura, Wintfield, Huang, & Goren., 2014). The risk for CVD can 
be decreased by living a healthy lifestyle with proper diet and exercise, and adherence to 
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medications, including the statins prescribed in order to lower LDL cholesterol and raise HDL 
cholesterol levels.  
Background and Significance 
 In the United States, cardiovascular disease (CVD) leads to more than 2,000 deaths per 
day and costs 108.9 billion dollars per year due to health care services, medication costs, and lost 
productivity of the affected individuals (Moore, Fuller, & Thanavaro, 2015). Dyslipidemia is a 
leading risk factor for CVD, and more than 32 million Americans 20 years and older have 
elevated blood cholesterol levels (Moore et al., 2015).  
 In 2012, more than 29 million Americans had diabetes (9.3% of the U. S. population), 
and more than 8 million were unaware of the diagnosis (American Diabetes Association, 2016). 
The death rate due to cardiovascular disease is 1.7 times greater for diabetics than people without 
a diagnosis of diabetes (American Diabetes Association, 2016). People living with diabetes with 
high cholesterol levels are at a much greater risk of dying from a cardiovascular complication 
than people without diabetes.  
 In Texas, there are approximately 1.8 million people who are currently diagnosed with 
diabetes, which is 13% of the state’s population (University Health System, 2017). More than 
400,000 people living with diabetes in Texas are undiagnosed (University Health System, 2017). 
In Bexar County alone, 11.8% of the population is diagnosed with diabetes, which is more than 
130,000 individuals (University Health System, 2017). Control of diabetes in this patient 
population is especially important, as diabetes is the fourth leading cause of death in Bexar 
County. Heart disease is the leading cause of death in the United States, in Texas, and in Bexar 
County as well (San Antonio Metropolitan Health District, 2009).   
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 Control of LDL cholesterol is improving in the diabetic population receiving treatment. 
Forty-five percent of United States residents treated for hypercholesterolemia were controlled 
with an LDL level <100 mg/dl between 1999 and 2000, which raised to 63.6% in 2009 and 2010 
(Farsaei et al., 2015). However, the improvement of HDL levels does not follow this increase, 
and remains problematic for those at risk, especially those with T2DM. Statin therapy not only 
decreases LDL cholesterol, but raises HDL cholesterol as well (American Heart Association, 
2016). Diet and exercise are the most effective lifestyle changes that can be made to lower LDL, 
increase HDL, and decrease risk for CVD (Macias Saint-Gerons et al., 2014). Not every patient 
will adhere to an appropriate diet and exercise regimen, however, and initiation of statin therapy 
for patients with increased risk as an adjunct to diet and exercise is appropriate for prevention of 
CVD in the diabetic patient.   
 One of the major predictors listed above that may cause a person diagnosed with diabetes 
to adhere to a medication regimen is lack of disease knowledge. Some studies have shown that 
education sessions provided to patients with diabetes can improve overall health knowledge and 
increase medication compliance rates. One study, in particular, conducted in the United Arab 
Emirates, utilized a 30-minute education session led by a diabetic educator that focused on the 
importance of adherence in addition to defining the disease process, talking about the 
medications prescribed and what they do inside the body, and answering any questions the 
participants had about the specific medications they were taking (Mohammed et al., 2016). The 
results of the study were significant for improvement of medication compliance in the 
intervention group (Mohammed et al., 2016). Another study conducted in Iran for diabetic 
patients used the Health Belief Model to educate patients about their disease in order to improve 
compliance to medications, and this intervention included six separate education sessions 
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pertaining to disease knowledge (Jalilian et al., 2014). Results showed that if patients were truly 
worried about their disease process and the complications, more effort would be taken to 
improve health outcomes by the patients.  The American Diabetes Association estimates the 
complications and costs of diabetes could be decreased significantly simply by increasing patient 
awareness and educating to improve prevention of comorbidities (Jalilian et al., 2014). If diabetic 
patients are non-adherent to diabetic medications, they are likely non-compliant with 
medications to prevent a disease they do not already have.  
 Several studies have been conducted in the United States as well, including a large pre-
post cohort study conducted at the Cleveland Clinic in which significant regression of coronary 
atheroma and reduction of cardiovascular events was shown using ultrasound analysis in patients 
prescribed moderate to high intensity statin therapy (Stegman, Puri, Shao, & Nicholls, 2014). 
Improvement was shown in all patients, including patients with T2DM. The national guidelines 
for practice produced by the American Heart Association and the American College of 
Cardiology strongly recommend initiating statin therapy in patients with T2DM aged 40 years 
and older, as the evidence shows that statin therapy is effective in decreasing bad cholesterol 
levels while raising good cholesterol levels in order to prevent cardiovascular disease (Stone et 
al., 2014).  
Assessment 
 The family practice clinic in which the quality improvement project was implemented is 
run by a group of 3 physicians, and 11 support staff including 1 practice administrator, 1 office 
manager, 3 administrative staff members, and 6 medical assistants. One diabetic educator is 
available 3 days per month for patient classes. Medicare and Medicaid are accepted, as well as 
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all other commercial insurances. The clinic has several contracts with managed care plans for 
patients aged 65 years and older for comprehensive disease management and primary care.  
Stakeholders are people or groups of people that have a vested interest in clinical 
decisions and improvements related to evidence supporting clinical decisions (Agency for 
Healthcare Research and Quality, 2014). The main stakeholders of this family practice clinic are 
the patients and families of patients, providers and support staff, and payers such as employers 
and insurance companies. The patients’ interests in the clinic stem from a concern for which 
aspects of the illness are most severe, what treatments are the most effective, and which options 
are the easiest to implement and maintain (Agency for Healthcare Research and Quality, 2014). 
Providers are the decision-makers, and they aim existing holes in the data pertaining to best 
treatment options and most harmful interventions, for the safe and effective management of 
patients (Agency for Healthcare Research and Quality, 2014). Providers must maintain an 
appropriate knowledge base to make the best treatment recommendations and must stay current 
on the most recent evidence-driven guidelines to provide quality care (Agency for Healthcare 
Research and Quality, 2014). Payers want to ensure that patients are treated with the best 
evidence-based treatment for expedition of healing, return to normal function, and to prevent 
complications related to disease processes that could increase direct and indirect costs of medical 
care (Agency for Healthcare Research and Quality, 2014). All stakeholders involved have a 
vested interest in the success of medical treatment and should support evidence-based practice 
and quality improvement measures.  
Patients of all ages are seen in the clinic, from pediatrics to geriatrics, with the majority 
age ranging from 42 to 77 years. There are 848 patients aged 65 years and older seen in this 
primary care clinic. The current percentage of patients with diabetes mellitus with LDL-C levels 
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of 70 mg/dl or less is 35.6%. The aim is to increase the percentage of patients with diabetes 
mellitus with LDL-C levels of 70 mg/dl or less to 70%.  
 The “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/ 
American Heart Association Task Force on Practice Guideline” states that patients with diabetes 
mellitus should have lipid panels drawn every 3 to 12 months, and 10 to 12 weeks after the 
initiation of statin therapy (Stone et al., 2014). Moderate intensity statin therapy should be 
initiated for patients aged 40 to 75 years with LDL-C levels of 70 mg/dl to 189 mg/dl (Stone et 
al., 2014). High intensity statin therapy should be initiated for patients aged 40 to 75 years with 
LDL-C levels of 190 mg/dl or greater (Stone et al., 2014). In order to appropriately manage 
diabetic patients at risk for cardiovascular disease, evidence indicates that statin therapy should 
be prescribed when indicated.  
Organizational Readiness for Change 
 The Practice Improvement Capacity Rating Scale is a tool for assessing readiness of an 
organization for implementation of quality improvement measures that scores a practice overall 
in colors, with the color red correlating to not ready, yellow to limited capacity for change, and 
green correlating to ready and capable for implementation of quality improvement measures 
(Robert Wood Johnson Foundation, 2014). In using this tool, one must first determine who to 
interview at the practice. The scoring of the tool not only has an overall color of red, yellow, or 
green, but each criterion is weighted on a scale of 1 to 3, with 1 being lowest importance and 3 
being the highest importance (Robert Wood Johnson Foundation, 2014). All criteria with a 
weight of 3 must be passed by the organization in order to receive a score of green. The clinic 
received an overall score of 255 by multiplying the scored questions by the weight of the 
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questions and adding each category to this total score. A score of 255 is considered green 
according to the scale, which indicates that the clinic ready and capable for QI work immediately 
(Robert Wood Johnson Foundation, 2014). 
Project Focus 
 The primary objective of this project is to improve the percentage of diabetic patients 
aged 65 years and older with a LDL-C level of 70 mg/dl or less from 35.6% to 70% and a statin 
therapy adherence rate increase from 20% to 90% by August 10, 2017.  The secondary objective 
is to increase the percentage of diabetic patients aged 65 and older prescribed statin therapy from 
62.6% to 80% by August 10, 2017. In order to accomplish these goals, the LDL-C level was 
drawn and measured in the blood prior to the quality improvement measure implementation in 
June 2017 and after the completion of the measure implementation on August 10, 2017. The 
participants will complete the MMAS-8 survey to assess patient medication adherence prior to 
the start of the improvement measure in June 2017 and again after the project completion on 
August 10, 2017.  
Summary and Strength of the Evidence 
The evidence for this project consists of 8 articles from peer-reviewed journals. Included 
in these eight articles is one clinical practice guideline, four cohort studies, one correlational 
study, and two descriptive studies. The findings are consistent for support of education for 
improving medication adherence in the diabetic patient population. There is also evidence for 
effectiveness of statin therapy in preventing cardiovascular disease. The overall strength of the 
articles is acceptable to use as evidence to support this project.  
 Several studies done in other countries, such as Iran, Spain, Japan, and the United Arab 
Emirates, support initiation of healthy lifestyle choice including diet and exercise (Osonoi et al., 
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2016), and initiation of statin therapy for management of dyslipidemia in patients at risk for 
CVD (Macias Saint-Gerons et al., 2014). Adherence is not a problem common to patients in the 
United States with T2DM, but common to many countries. Level 4 evidence in the form of a 
large cohort study in the United Arab Emirates indicated that adherence could be improved using 
educational sessions about T2DM, its associated risk factors, and recommended treatment 
regimens (Mohammed et al., 2016).  
 A large clinical trial conducted at the Cleveland Clinic in the United States compared 
rosuvastatin and atorvastatin on regression of coronary atheroma in diabetic and non-diabetic 
patients. It showed a significant improvement in patients with established atherosclerosis taking 
one of these medications over the course of 24 months, with intravascular ultrasound 
measurements taken to visualize regression of plaque in the arteries (Stegman et al., 2014). The 
evidence in this study, a controlled trial over 2 years, is graded Level 3 for strength of evidence. 
This study does include the diabetic patient, and is reliable for generalization of statin therapy for 
the T2DM population.  
 National guidelines are in place for initiation of statin therapy for cholesterol 
management of diabetic patients with LDL levels >70 mg/dl. This strength of evidence is Level 
1, and the recommendations include statin therapy for T2DM patients with elevated LDL levels 
to include moderate to intensive statin therapy (Stone et al., 2014).  
 The evidence is international in support of utilization of statin therapy in the diabetic 
population in order to control overt CVD and to prevent CVD in those not yet affected by this 
complication. It is important to control the risk for all complications in T2DM patients, and with 
heart disease holding fast to its rank as the leading cause of death in the general population, this 
complication becomes one of ultimate importance for people living with T2DM.  
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Methods 
Project Intervention 
 In order to accurately measure the improvement of LDL-C cholesterol levels in the 
diabetic population aged 65 and older in this clinic, a review of electronic medical records took 
place to retrieve the baseline cholesterol levels from previous laboratory studies taken. During 
the patient’s regularly scheduled appointment, the MMAS-8 was completed by the patient as part 
of normal patient care routine for the purpose of measuring medication compliance. During the 
patient appointment, an education handout pertaining to cholesterol control and cardiovascular 
disease prevention was given to the patient scoring a 6 or less on the MMAS-8 when discussing 
current statin therapy increase or initiation of statin therapy for prevention of cardiovascular 
disease.  
 Patients were scheduled for return appointment at the end of the intervention 
implementation period for a redraw of blood in laboratory for LDL-C levels and reissued the 
MMAS-8 to assess for improvement in medication compliance. The scores were assessed and 
evaluated for significant improvement in LDL-C levels and medication adherence in order to 
ensure optimal outcomes for this population.  
 In order to confirm that the project, if successful, can be sustained by the providers and 
other staff members, a 30-minute staff meeting was held in which the project was explained, 
including each person’s role. The providers will participate in the initial education session during 
the patient appointments to ensure continuity of care. All staff members were educated on how to 
find the handouts for education at the American Diabetes Association website.  
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Organizational Barriers and Facilitators 
 This clinic possesses many strengths that can facilitate successful completion of this 
quality improvement measure. The staff utilizes the electronic health record consistently, which 
makes it easier to track the overall health of the patient population, and to track which areas may 
need further attention. Parts of the electronic health record are available to patients through the 
patient portal as well, making it easier for them to read and interpret their own test results and to 
assist in their own care plan. The clinic has a strong reputation in the community, and there is 
facilitation of trust between patients, families, and providers. Trust is apparent between members 
of the health care team in the clinic, which should make it simpler to provide quality overall 
patient care. Network partnerships exist with managed care plans for the aging population seen 
in the organization, which makes more resources available to provide a holistic model of care. 
The office is run efficiently, with short wait times for patients and decreased stress on providers 
and support staff. All three providers are proficient in the Spanish language. This facilitates trust 
between patients seen in the clinic who speak English as a second language or not at all. Fluency 
in Spanish also allows the providers to appropriately educate the entire patient population seen in 
this organization. The clinic has a number of patients with multiple chronic conditions, such as 
diabetes, and with the assistance of the diabetic educator the clinic is able to provide quality care 
from an interdisciplinary approach.  
 Some weaknesses were also discovered in this organization. There is a lack of written 
educational materials available in the clinic waiting area or examination rooms. Written 
education is a supplement for providers that can assist the health care team in ensuring the 
patient retains education initiated during patient appointments. The continuity of care for some 
patients who do not come to scheduled appointments is an area of concern, as some patients with 
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chronic conditions are not attending recommended follow-up appointments to evaluate progress 
of disease management and medication adherence. Medication cost is an issue identified by some 
of the staff members in the organization, as they have spoken with patients who are concerned 
that they will not be able to afford all of the medications required to control their conditions and 
achieve optimal outcomes. Some procedures a patient may require, such as radiological 
examinations, have to be done off premises as these resources are not available in this clinic 
setting, which can be a barrier to appropriate disease management of some patients. The clinic is 
growing in patient number, however the small space allotted in the building for the clinic makes 
it difficult to expand the number of patients accepted into the practice. There is limited funding 
available to expand the clinic to a larger space, which poses another obstacle to providing care to 
a larger patient population. Lastly, slowed access to referred specialist consultations for patients 
with chronic disease management can impede the holistic approach to care for these individuals.  
 The west side of San Antonio is a growing community, with new homes being 
constructed daily and new businesses opening everywhere. Given this growing community, the 
patient population is expected to grow. With this clinic’s positive reputation, many new patients 
are expected to choose this clinic as a primary care home for health care needs. A large part of 
the growing population is in the age range of 65 years and older, and these patients are choosing 
managed care plans that may have established partnerships with the organization. Urgent care 
centers, free-standing emergency rooms, and a small community hospital already exist in the 
area, as well, which could lead to more referrals post-discharge for follow-up care or 
establishment of primary care.  
 Some external threats have been established through the SWOT analysis for this family 
practice care setting. The number of specialty physicians on this side of the city are fewer than 
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the number needed, and the wait for patient referrals may be extended, leaving the primary care 
provider with the responsibility of managing multiple chronic conditions in some patients 
awaiting specialty care. Also, the patients are allowed to choose a primary care provider, and 
there are many choices for such care on the west side of San Antonio. Patients without insurance 
due to unemployment or other factors may not be able to seek primary care because of the 
inability to afford health care costs associated with clinic visits. Insurance companies also 
reimburse these organizations according to value-based care plans in some instances, and this 
may lead to decreased income for fee-for-service clinics.  
 This primary care clinic has the potential to make a difference and to utilize evidence-
based measures to improve the quality of health care in the area, and there are many barriers and 
facilitators to the achievement of this goal, as listed above. Knowledge of the clinic’s internal 
strengths and weaknesses, as well as external opportunities and threats will aid in completion of 
a successful quality improvement intervention. 
Results 
 A total of 14 males (42.4%) and 19 females (57.6%), aged 65 years and older participated 
in the project. 16 participants were White (48.5%), 11 Hispanic (33.3%), 4 African American 
(12.1%), and 2 Asian/Pacific Islander (6.1%). All 33 participants had both an active diagnosis of 
diabetes mellitus and hyperlipidemia.  
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Table 1 
Demographic Characteristics of Study Participants 
Characteristic Percentage Mean SD 
Gender 
     Male 
     Female 
 
 
 
42.40 
57.80 
1.58 0.50 
Ethnicity 
    Caucasian 
    Hispanic 
    African American 
    Asian/Pacific Islander 
 
48.50 
33.30 
12.10 
6.10 
1.97 1.05 
    
Note. SD = Standard Deviation 
Control of Cholesterol 
 After the 10-week project implementation period, LDL-C levels of less than 100 mg/dl 
were controlled 42.4% of the time, a 21.2% increase of the pre-intervention control rate of 
21.2%. The LDL-C control for diabetic patients aged 40 and up is recommended to remain at 70 
mg/dl or less, and this was found in only 12.1% of the participants. However, this small 
percentage is an increase of 12.1% since none of the participants were controlled at less than 70 
mg/dl. Table 2 represents LDL-C levels before and after implementation.  
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Table 2 
LDL-C Laboratory Values Before and After Education Intervention 
Patient Number Pre-Intervention 
LDL-C  
Post-Intervention 
LDL-C 
1 127 98 
2 95 64 
3 87 64 
4 135 102 
5 121 94 
6 140 148 
7 111 114 
8 119 96 
9 106 108 
10 183 166 
11 81 64 
12 158 122 
13 137 116 
14 130 88 
15 99 98 
16 109 74 
17 77 78 
18 108 92 
19 281 177 
20 132 133 
21 98 64 
22 153 115 
23 206 127 
24 120 119 
25 97 84 
26 163 104 
27 103 112 
28 135 128 
29 140 101 
30 132 120 
31 188 118 
32 118 78 
33 140 102 
Mean 131.18 105.09 
SD 25.56  
Note. SD = Standard Deviation 
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Adherence to Statin Therapy Regimen 
 Medication adherence improved among the group of participants from 0% to 34.46%. 
This percentage increase was calculated using the formula (y2-y1)/y1x100. For statistical 
analysis of the MMAS-8 scores, a paired t-test was utilized to determine significance of the 
difference in scores pre- and post-implementation of the project among participants. The results 
were consistent with the desired outcome, in that post-intervention adherence scores (M = 5.36, 
SD = 0.82) were higher than the pre-intervention adherence scores (M = 7.21, SD = 0.22). The 
difference between pre- and post-implementation scores was statistically significant (M = -1.85, 
SD = 1.35, t (32) = -7.87, p < .05). Table 3 displays the paired t-test statistical analysis for 
medication adherence scores before and after the intervention.  
Table 3 
Medication Adherence Paired T-Test Results 
 
Mean SD SEM 
95% CI for Mean  
Difference 
t df 
 
Lower Upper 
 Participants’ MMAS-8 
score pre- and post-
intervention  
-1.85 1.35 0.24 -2.33 -1.37 -7.87 32  
Note. SD = Standard Deviation, CI = confidence interval, SEM = Standard Error of the Mean.  
*p < .05. 
 
 Although the target LDL-C level recommended by the American College of Cardiology 
and the American Heart Association of 70 mg/dl or less was not met, this project’s duration was 
limited at only 10 weeks. Given more time, if adherence is maintained, this population could 
very well meet the target LDL-C level.  
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Discussion 
 The MMAS-8 medication adherence scale was consistently given to patients that entered 
the office over the age of 65 with a diagnosis of diabetes and hyperlipidemia over the first 2 
weeks of project implementation. This was necessary because the implementation of education 
handout and information session during scheduled appointments could not proceed without an 
adherence scale in which to score the patient’s baseline. The intake period of 2 weeks was 
necessary in order to have enough time to follow up in the same 10-week period and re-score the 
patients using the MMAS-8 scale.  
 Of these 35 patients selected, 35 received education handouts and materials based on the 
MMAS-8 score of 7 or less. At the end of the 10-week implementation period, these patients 
were rescreened with MMAS-8 during the follow-up appointment. The percentage increase of 
34.46% indicates that many of these patients did make adjustments to his or her daily routine 
based on the education handout and session provided. The LDL-C levels, for the most part, 
showed this change in lifestyle with the correlation of decreased laboratory values, though the 
goal value of 70 mg/dl was not met.  
 Improvement of patient knowledge is a basic plan for controlling diabetes and 
complications from the disease (Jalilian et al., 2014). Verbal discussion about risks for 
cardiovascular disease and what that means for the patient, as well as a printed handout from the 
American Diabetes Association about cholesterol did show reduction in laboratory values and 
improved adherence over the 10-week implementation period.  
Statin therapy has been proven to reduce the risk of cardiovascular events (Stegman et al., 
2014). If the medication is only taken every other day, the patient does not receive the full 
benefit of the drug. Poor adherence at the beginning of this study, with scores of 7 or less on the 
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MMAS-8, did correlate with LDL-C levels above the recommended target LDL-C of 70 mg/dl. 
With improved adherence, the LDL-C levels did decrease as hoped, and did meet the in 4 
participants of the original 35 patients selected (11.43%).  
Limitations 
 The sample size of this project was small with only 35 participants, due to the time limit 
of 10 weeks for implementation. No earlier implementation could have taken place, as there was 
time allotted to educate and train staff members about the project and what each person’s role 
would be. Patients who were initially screened and did not follow up were not included in the 
final number of participants, because there was no way to measure adherence for these 
individuals. The short time allotted for implementation of the project is also considered a 
limitation. A longer time period for implementation may result differently.  
Recommendations 
 Out of 52 patients screened with MMAS-8, 35 scored at or 7 or below in a 2-week time 
period, and hence received an education session and a paper handout about cholesterol and 
cardiovascular disease prevention. Diabetic patients need education about the risk for cardiac 
events related to diabetes, and if only 2 weeks yielded 35 patients from an age group of 65 and 
older who were not adhering to his or her medication regimen, a longer study may produce more 
patients with the same issue. This education should hence be provided as standard of care for the 
patients seen in clinic with a diagnosis of diabetes and/or hyperlipidemia.  
Implications for Practice 
 None of the 52 patients diagnosed with diabetes and hyperlipidemia were screened for 
medication adherence prior to implementation of this quality improvement project. Of the 
patients screened during the project implementation, 100% of patients were initially scored as 
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non-adherent with a score of 7 or less on the MMAS-8. After implementation, the 0% adherence 
rate increased to 45.71% after project completion, with 16/35 patients scoring at 8 or above on 
the MMAS-8. This finding indicates that patients should be assessed for adherence regularly, 
either by scale or by asking the patient and/or family members about medication regimens. 
Reinforcement of education at follow-up appointments by discussing aspects of the patient’s 
individualized treatment plan can assist in reminding patients about goals of treatment.  
 Knowledge empowers patients to participate in self-care activities, and with this 
education about cholesterol, patients are empowered to monitor levels with the physician to 
monitor improvement of the disease process. If diabetic patients track blood glucose levels and 
pay attention to the glycosylated hemoglobin levels in the physician’s office, the LDL-C level 
should be added to that list for the patient to track with the provider. They will remain informed 
in this manner, and able to participate in the treatment plan, thus optimizing patient outcomes.  
 In order for this project to be sustained as a standard of care in the clinic, there must be a 
method of supervision in place for implementation to continue. The Advanced Practice 
Registered Nurse can offer supervision in this instance. Implementation and continuance of the 
American College of Cardiology/American Heart Association guidelines in order to ensure 
diabetic patients are placed either on moderate or high-intensity statin therapy and maintain 
LDL-C levels of 70 mg/dl or less has the capacity to impact the diabetic patient population 
significantly. The Advanced Practice Registered Nurse is able to screen patients for diabetes and 
high cholesterol, educate about medication adherence and disease management, and give a 
detailed explanation of any laboratory results analysis. As a provider, the APRN has the ability 
to positively affect the diabetic population by making this group less susceptible to 
cardiovascular disease through statin therapy adherence.  
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Appendix A: Practice Improvement Capacity Rating Scale 
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Appendix B: SWOT Analysis from Family Practice Clinic 
Strengths Weaknesses 
§ Electronic Health Record foundation 
§ Reputation for quality healthcare 
§ Patient Portal present on website 
§ Strong medical staff and strong 
leadership 
§ Problem-solving 
§ Trust between staff members 
§ Network partnerships (ex. WellMed) 
§ High level of efficiency 
§ Spanish language proficiency of 
providers 
§ Strong relationships with patients and 
families 
§ Interdisciplinary approach 
§ Lack of available written educational 
resources 
§ Difficulties in continuity of care 
§ Lack of appropriate medication costs  
§ Limited procedural/diagnostic 
capabilities 
§ Small clinic with some tight spaces 
§ Slowed access to referring physician 
documentation 
§ Limited budget 
Opportunities Threats 
§ Growing metropolitan community 
§ Increasing aging and managed care 
population 
§ Expanding community health care 
programs 
§ Competition for specialty referring 
physicians 
§ Patient choice of primary care 
provider 
§ Lack of insurance related to high 
unemployment rate 
§ Reduction of government 
reimbursement 
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Appendix C: Morisky Medication Adherence Scale (MMAS-8) 
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Appendix D: Education Handouts for Quality Improvement Project 
 
 
STATIN THERAPY QUALITY IMPROVEMENT INITIATIVE 38 
 
 
 
